Actively Recruiting
SBRT With Atezo/Bev for HCC
Led by Abramson Cancer Center at Penn Medicine · Updated on 2026-02-20
18
Participants Needed
1
Research Sites
226 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A phase I dose escalation and pharmacodynamic study of repeated dose stereotactic body radiotherapy (SBRT) administered with concurrent atezolizumab and bevacizumab for patients with advanced hepatocellular carcinoma (HCC)
CONDITIONS
Official Title
SBRT With Atezo/Bev for HCC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have hepatocellular carcinoma (HCC) that cannot be treated with surgery or ablation due to disease extent, other health issues, or technical reasons
- Require systemic therapy for advanced HCC
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104-4283
Actively Recruiting
Research Team
E
Edgar Ben-Josef, MD
CONTACT
T
Taylor Siegal
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here